More on AGIO
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $34.16 |
|
|||
| Open | $34.64 | ||||
| 52 Wk High | $71.49 | ||||
| 52 Wk Low | $33.50 | ||||
| Day High | $35.00 | ||||
| Day Low | $34.30 | ||||
| P/E | N/A | ||||
| EPS | $-1.18 | ||||
| Volume | 16,699 | ||||
- Form S-8 AGIOS PHARMACEUTICALS,
- Form 8-K AGIOS PHARMACEUTICALS, For: Jun 18
- Form 4 AGIOS PHARMACEUTICALS, For: Jun 13 Filed by: Owen Adams Catherine
- Form 4 AGIOS PHARMACEUTICALS, For: Jun 13 Filed by: CAPELLO JEFFREY D
- Agios Pharma (AGIO) PT Raised to $54 at H.C. Wainwright
- Agios presents Phase 3 sickle cell disease trial results at EHA conference
- Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
- Agios Pharma (AGIO) PT Lowered to $31 at JPMorgan
- Agios licenses blood disorder drug from Oscotec for $25 million upfront
- Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
Entities mentioned with AGIO
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- PDUFA | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
